查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1656896

主动式植入式医疗设备的全球市场:洞察，竞争情形，市场预测:2032年

Active Implantable Medical Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

主动式植入式医疗设备市场规模预计在 2024 年达到 25,360,780 百万美元。预计预测期内（2025-2032 年），市场复合年增长率为 7.82%，到 2032 年将达到 462.8118 亿美元。全球主动植入式医疗器材市场受到塑造医疗器材格局的各种因素的驱动。首先，神经系统疾病、心血管疾病和听力障碍等慢性疾病的发生率不断上升，推动了对主动植入式医疗设备的需求。此外，为了满足这种需求，世界各地的产品开发活动激增，各家公司都投资于创新解决方案来解决这些复杂的健康问题。此外，人们对慢性病的认识不断提高和早期诊断也鼓励及时干预和治疗，从而进一步推动市场发展，这反过来又推动了对先进的主动植入式医疗设备的需求。因此，疾病的增加、产品开发的创新以及人们认识的不断提高都将在预测期（即 2025-2032 年）内推动有源植入式医疗设备领域实现强劲的成长轨迹。

根据世界卫生组织（WHO）（2024）的最新数据，到2050年，约有25亿人将出现听力损失，7亿人需要復健治疗。一个重要因素是不安全的听力习惯，使超过 10 亿年轻人面临风险。 80% 的深度听力损失发生在中低收入国家。此外，听力损失会随着年龄的增长而增加，影响 60 岁以上人口的 25％ 以上。因此，听力损失病例的增加正在迅速增加对人工耳蜗和中耳植入物等先进有效的解决方案的需求。这些设备透过直接刺激听觉神经或增强声音振动的传输来解决听力损失问题，为患者提供改善的听力和更好的生活品质。

根据世界卫生组织 (WHO) 的数据，癫痫是最普遍的神经系统疾病之一，影响全球约 5,000 万人（2024 年）。此外，神经系统疾病影响全球三分之一以上的人口，是导致疾病和残疾的主要原因。帕金森氏症、癫痫和慢性疼痛等神经系统疾病正在推动对深部脑部刺激器和脊髓刺激器等主动植入式装置的需求。

此外，根据世界心臟联盟 (2024) 的数据，在全球约 6.2 亿人口中，每 13 人中就有 1 人患有心臟或循环系统疾病。其中3.4亿人居住在亚洲和澳大利亚，1亿人居住在欧洲。冠心病影响2亿人，其中包括1.1亿男性和8000万名女性。此外，有 5,600 万名女性患有中风，4,500 万名男性患有中风，1,300 万人患有先天性心臟病，其中许多人可能未被诊断出来。因此，心律调节器、除颤器和心室辅助装置透过调节心臟功能在管理心血管疾病方面发挥至关重要的作用，从而促进全球整体主动植入式医疗设备市场的发展。

有源植入式医疗器材 (AIMD) 市场正在经历快速成长，这得益于全球产品开发、研发工作和监管部门批准的重大进步。美敦力、波士顿科学和雅培等大公司处于这些创新的前沿，提供新设备来治疗重要的医疗状况，特别是在心臟、神经和听力领域。

本报告提供全球主动式植入式医疗设备市场相关调查，提供市场概要，以及各产品类型，各终端用户，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 主动式植入式医疗设备市场报告的简介

第2章 主动式植入式医疗设备市场摘要整理

第3章 竞争情形

第4章 法规分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第5章 主动式植入式医疗设备市场主要原因分析

  • 主动式植入式医疗设备市场促进因素
  • 主动式植入式医疗设备市场阻碍因素与课题
  • 主动式植入式医疗设备市场机会

第6章 主动式植入式医疗设备市场上波特的五力分析

第7章 主动式植入式医疗设备市场评估

  • 各产品类型
    • 植入式心血管设备
    • 植入式神经刺激设备
    • 植入型助听器
    • 其他
  • 各终端用户
    • 医院
    • 门诊病人手术中心
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

第8章 主动式植入式医疗设备市场企业及产品简介

  • Medtronic plc
  • Johnson and Johnson Services, Inc.
  • Abbott
  • Boston Scientific Corporation
  • LivaNova PLC.
  • Axonics, Inc.
  • Aleva Neurotherapeutics
  • Sonova Holding AG
  • Bioventus Inc.
  • CARMAT
  • Jarvik Heart Inc.
  • BIOTRONIK SE & Co. KG
  • MicroTransponder Inc.
  • MED-EL Medical Electronics
  • NeuroPace, Inc.
  • NEVRO CORP.
  • Shree Pacetronix
  • Cochlear Ltd.
  • Berlin Heart
  • Blackrock Neurotech

第9章 KOL的见解

第10章 计划的方法

第11章 关于DelveInsight

第12章 免责声明和咨询方式

Product Code: DIMDCL0465

Active Implantable Medical Devices Market by Product Type (Implantable Cardiovascular Devices {Implantable Cardioverter Defibrillators, Ventricular Assist Devices, Implantable Pacemakers, and Implantable Heart Monitors/Insertable Loop Recorders}, Implantable Neurostimulators {Deep Brain Stimulators, Spinal Cord Stimulators, Sacral Nerve Stimulators, and Others}, Hearing Implants, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the Increasing prevalence of chronic diseases such as neurological disorders, cardiovascular disorders, and hearing disability, Increased in product development activities across the globe, and Increased awareness and early diagnosis across the globe.

The active implantable medical devices market was valued at USD 25,360.78 million in 2024, growing at a CAGR of 7.82% during the forecast period from 2025 to 2032 to reach USD 46,281.18 million by 2032. The global active implantable medical devices market is propelled by a convergence of factors shaping the medical device landscape. Firstly, the increasing prevalence of chronic diseases, such as neurological disorders, cardiovascular disorders, and hearing disability, fuels the demand for active implantable medical devices. Additionally, in response to this demand, there has been a surge in product development activities worldwide, with companies investing in innovative solutions to address these complex health issues. Moreover, enhanced awareness and early diagnosis of chronic diseases further boost the market by encouraging timely intervention and treatment, which in turn drives the need for advanced active implantable devices. This convergence of increasing disease prevalence, innovation in product development, and heightened awareness collectively foster a robust growth trajectory for the active implantable medical device sector during the forecast period from 2025 to 2032.

Active Implantable Medical Devices Market Dynamics:

According to the latest data from the World Health Organization (2024), by 2050, nearly 2.5 billion people will experience hearing loss, with 700 million needing rehabilitation. A significant factor is unsafe listening habits, placing over 1 billion young adults at risk. The majority of severe hearing loss cases 80% occur in low- and middle-income countries. Additionally, hearing loss increases with age, affecting over 25% of individuals over 60. Thus, due to the rise in cases of hearing loss, the demand for advanced and effective solutions like cochlear implants and middle-ear implants is rising rapidly. These devices address hearing impairments by directly stimulating the auditory nerve or enhancing the transmission of sound vibrations, offering patients improved auditory perception and quality of life.

Additionally, Epilepsy, one of the most widespread neurological disorders, affects approximately 50 million people worldwide, according to the World Health Organization (2024), with nearly 80% of cases occurring in low- and middle-income countries. Moreover, over one-third of the global population is affected by neurological conditions, making them a leading cause of illness and disability. Neurological disorders such as Parkinson's disease, epilepsy, and chronic pain are fueling the demand for active implantable devices like deep brain and spinal cord stimulators, which provide targeted nerve modulation.

Moreover, According to the World Heart Federation (2024), globally, approximately 620 million people 1 in 13 were living with heart and circulatory diseases. Of these, 340 million cases are in Asia and Australia, and 100 million are in Europe. Coronary heart disease affected 200 million people, including 110 million men and 80 million women. Additionally, there were 56 million female stroke survivors and 45 million male survivors, while 13 million people lived with congenital heart disease, with many cases potentially undiagnosed. Thus, pacemakers, defibrillators, and ventricular assist devices play a crucial role in managing cardiovascular diseases by regulating heart function and thereby boosting the overall market of active implantable medical devices across the globe.

Furthermore, the Active Implantable Medical Devices (AIMD) market is experiencing rapid growth, fueled by significant advancements in product development, R&D efforts, and regulatory approvals across the globe. Leading companies such as Medtronic, Boston Scientific, and Abbott are spearheading these innovations, bringing new devices to address critical medical conditions, especially in cardiac, neural, and hearing-related applications.

For instance, in December 2023, CARMAT achieved a major milestone with the first implantation of the Aeson(R) total artificial heart in a patient with a cardiac tumor. By January 2024, the company had completed 50 successful implants of this groundbreaking device, which is crucial for patients with end-stage heart failure, offering a new lease on life for those awaiting heart transplants.

Thus, the factors mentioned above are expected to boost the overall market of active implantable medical devices across the globe during the forecast period from 2025 to 2032.

However, the high cost of active implantable devices in developing countries and the increase in product recalls across the globe may hinder the future market of active implantable medical devices across the globe during the forecasted period.

Active Implantable Medical Devices Market Segment Analysis:

Active Implantable Medical Devices Market by Product Type (Implantable Cardiovascular Devices {Implantable Cardioverter Defibrillators, Ventricular Assist Devices, Implantable Pacemakers, and Implantable Heart Monitors/Insertable Loop Recorders}, Implantable Neurostimulators {Deep Brain Stimulators, Spinal Cord Stimulators, Sacral Nerve Stimulators, and Others}, Hearing Implants, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The implantable cardioverter defibrillators category in the active implantable medical devices market is estimated to dominate the market with a market share of 35.21% in 2024. Implantable cardioverter defibrillators (ICDs) are playing a pivotal role in boosting the overall market of active implantable medical devices (AIMDs) by addressing the growing global burden of cardiovascular diseases, particularly life-threatening arrhythmias. ICDs are life-saving devices designed to monitor heart rhythms and deliver electrical shocks to restore normal heartbeats in cases of sudden cardiac arrest (SCA) or ventricular arrhythmias. With the increasing prevalence of conditions such as coronary artery disease, heart failure, and inherited arrhythmogenic disorders, the demand for ICDs has surged. According to the World Heart Federation (2024), around 60 million people globally suffer from atrial fibrillation (AF), a common form of arrhythmia that increases the risk of stroke, heart failure, and blood clots. People with AF are five times more likely to experience a stroke. In 2021, more than 500,000 people in Australia were affected by AF, as reported by the Australian Institute of Health and Welfare. These implantable cardioverter defibrillator devices are critical for preventing sudden cardiac arrest, a leading cause of death worldwide, which underscores their importance in modern cardiology.

Technological advancements in ICDs are also driving their adoption and market expansion. Modern ICDs feature dual- and triple-chamber capabilities, remote monitoring systems, and sophisticated algorithms for detecting and treating arrhythmias with higher precision. These innovations enhance patient safety and improve device efficacy while reducing unnecessary shocks, a key concern in older models. Subcutaneous ICDs (S-ICDs) have emerged as a transformative innovation, offering an entirely extravascular option for patients with limited venous access or a higher risk of infection. The introduction of S-ICDs not only expands the patient pool but also addresses concerns about lead-related complications, making them a preferred choice among certain patient groups. For instance, in October 2023, Medtronic gained FDA approval for the Aurora EV-ICD(TM) MRI SureScan(TM) (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV(TM) MRI SureScan(TM) defibrillators, which treat dangerously fast heart rhythms that can cause sudden cardiac arrest (SCA). The Aurora EV-ICD provides lifesaving defibrillation, anti-tachycardia pacing (ATP), and backup (pause-prevention) pacing therapy with a device that is similar in size, shape, and lifetime to typical transvenous ICDs.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of active implantable medical devices across the globe.

North America is expected to dominate the overall active implantable medical devices market:

Among all regions, North America is estimated to hold the largest share of 40.49% in the global active implantable medical devices market in 2024, growing at a CAGR of 6.64% during the forecast period from 2025 to 2032. This can be attributed to the increasing prevalence of hearing disability, heart-associated disorders, rise in neurodegenerative disorders, among others. Moreover, the increased awareness and early diagnosis of chronic diseases further boost the market by encouraging timely intervention and treatment, which in turn drives the need for advanced active implantable devices. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of active implantable medical devices across the region.

According to data provided by the Centers for Disease Control and Prevention (CDC) in November 2023, approximately 6,520 cases of permanent hearing loss were reported in 2021 in the United States. The demand for advanced hearing solutions thus rises, particularly cochlear implants and middle-ear implants, is surging as they offer effective alternatives for individuals with severe to profound hearing loss who cannot benefit from traditional hearing aids thereby boosting the overall market of active implantable medical devices across the region.

Additionally, as per the data provided by the Centers for Disease Control and Prevention 2024, coronary heart disease is the most common type of heart disease, with about 1 in 20 adults on average aged 20 and above suffering from coronary heart disease in the United States. Active implantable devices, such as implantable cardioverter defibrillators (ICDs), pacemakers, and cardiac resynchronization therapy (CRT) devices, are critical in managing these conditions. The high prevalence of CHD in North America, attributed to sedentary lifestyles, unhealthy diets, and aging populations, has created a significant patient pool requiring these life-saving devices.

Furthermore, various key product approvals in the region are some of the other factors that are influencing the positive growth of the market in the United States. For instance, in February 2024, Boston Scientific Corporation announced that the U.S. Food and Drug Administration (FDA) approved the WaveWriter(TM) SCS Systems for the treatment of chronic low back and leg pain.

Thus, the above-mentioned factors are expected to escalate the market of active implantable medical devices in the region.

Active Implantable Medical Devices Market Key Players:

Some of the key market players operating in the active implantable medical devices market include Medtronic plc., Johnson and Johnson Services, Inc., Abbott, Boston Scientific Corporation, LivaNova PLC., Axonics, Inc., Aleva Neurotherapeutics, Sonova Holding AG, Bioventus Inc., CARMAT, Jarvik Heart Inc., BIOTRONIK SE & Co. KG, MicroTransponder Inc., MED-EL Medical Electronics, NeuroPace, Inc., NEVRO CORP., Shree Pacetronix, Cochlear Ltd., Berlin Heart, Blackrock Neurotech, and others.

Recent Developmental Activities in the Active Implantable Medical Devices Market:

  • In July 2023, Abbott introduced the AVEIR(TM) dual chamber leadless pacemaker, the first of its kind to treat arrhythmias in both the right atrium and ventricle, greatly expanding access to this technology for U.S. patients.
  • In December 2022, Abbott launched the Eterna(TM) spinal cord stimulation system, the smallest implantable rechargeable spinal cord stimulator. It incorporates Abbott's low-dose BurstDR(TM) stimulation, offering better pain management outcomes and setting a new standard in chronic pain treatment.
  • In November 2022, Cochlear received FDA approval for its Nucleus(R) 8 Sound Processor, the smallest and lightest behind-the-ear processor on the market, incorporating Bluetooth LE Audio technology. This innovation improves connectivity and usability for patients with hearing loss.

Key Takeaways From the Active Implantable Medical Devices Market Report Study

  • Market size analysis for current active implantable medical devices size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the active implantable medical devices market.
  • Various opportunities available for the other competitors in the active implantable medical devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current active implantable medical devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for active implantable medical devices market growth in the coming future?

Target Audience Who Can be Benefited From This Active Implantable Medical Devices Market Report Study

  • Active implantable medical device product providers
  • Research organizations and consulting companies
  • Active implantable medical devices-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in active implantable medical devices
  • Various end-users who want to know more about the active implantable medical devices market and the latest technological developments in the active implantable medical devices market.

Frequently Asked Questions for the Active Implantable Medical Devices Market:

1. What are active implantable medical devices?

  • Active implantable medical devices are advanced medical devices designed for implantation within the human body. These devices incorporate electronic components that interface with the body's physiological systems to effectively monitor & regulate biological functions.

2. What is the market for active implantable medical devices?

  • The active implantable medical devices market was valued at USD 25,360.78 million in 2024, growing at a CAGR of 7.82% during the forecast period from 2025 to 2032 to reach USD 46,281.18 million by 2032.

3. What are the drivers for the global active implantable medical devices market?

  • The global active implantable medical devices market is propelled by a convergence of factors shaping the medical device landscape. Firstly, the increasing prevalence of chronic diseases, such as neurological disorders, cardiovascular disorders, and hearing disability, fuels the demand for active implantable medical devices. Additionally, in response to this demand, there has been a surge in product development activities worldwide, with companies investing in innovative solutions to address these complex health issues. Moreover, enhanced awareness and early diagnosis of chronic diseases further boost the market by encouraging timely intervention and treatment, which in turn drives the need for advanced active implantable devices. This convergence of increasing disease prevalence, innovation in product development, and heightened awareness collectively foster a robust growth trajectory for the active implantable medical device sector during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global active implantable medical devices market?

  • Some of the key market players operating in the active implantable medical devices are Medtronic plc., Johnson and Johnson Services, Inc., Abbott, Boston Scientific Corporation, LivaNova PLC., Axonics, Inc., Aleva Neurotherapeutics, Sonova Holding AG, Bioventus Inc., CARMAT, Jarvik Heart Inc., BIOTRONIK SE & Co. KG, MicroTransponder Inc., MED-EL Medical Electronics, NeuroPace, Inc., NEVRO CORP., Shree Pacetronix, Cochlear Ltd., Berlin Heart, Blackrock Neurotech, and others.

5. Which region has the highest share in the global active implantable medical devices market?

  • North America region is anticipated to dominate the overall active implantable medical devices market due to the increasing prevalence of hearing disability, heart-associated disorders, and rise in neurodegenerative disorders, among others. Moreover, the increased awareness and early diagnosis of chronic diseases further boost the market by encouraging timely intervention and treatment, which in turn drives the need for advanced active implantable devices. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of active implantable medical devices across the region.

Table of Contents

1. Active Implantable Medical Devices Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Active Implantable Medical Devices Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Active Implantable Medical Devices Market Key Factors Analysis

  • 5.1. Active Implantable Medical Devices Market Drivers
    • 5.1.1. Increasing prevalence of chronic diseases such as neurological disorders, cardiovascular disorders, and hearing disability
    • 5.1.2. Increased product development activities across the globe
    • 5.1.3. Increased awareness and early diagnosis
  • 5.2. Active Implantable Medical Devices Market Restraints and Challenges
    • 5.2.1. High cost of active implantable devices in developing countries
    • 5.2.2. Product recalls and failures due to safety issues
  • 5.3. Active Implantable Medical Devices Market Opportunities
    • 5.3.1. Integration of next-generation AI enhancements in active implantable

6. Active Implantable Medical Devices Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Active Implantable Medical Devices Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Implantable Cardiovascular Devices
      • 7.1.1.1. Implantable Cardioverter Defibrillators
      • 7.1.1.2. Ventricular Assist Devices
      • 7.1.1.3. Implantable Pacemakers
      • 7.1.1.4. Implantable Heart Monitors/Insertable Loop Recorders
    • 7.1.2. Implantable Neurostimulators
      • 7.1.2.1. Deep Brain Stimulators
      • 7.1.2.2. Spinal Cord Stimulators
      • 7.1.2.3. Sacral Nerve Stimulators
      • 7.1.2.4. Others
    • 7.1.3. Hearing Implants
    • 7.1.4. Others
  • 7.2. By End-User
    • 7.2.1. Hospitals
    • 7.2.2. Ambulatory Surgical Centers
    • 7.2.3. Others
  • 7.3. By Geography
    • 7.3.1. North America
      • 7.3.1.1. United States Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.1.2. Canada Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.1.3. Mexico Active Implantable Medical Devices Market Size in USD Million (2022-2032)
    • 7.3.2. Europe
      • 7.3.2.1. France Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.2.2. Germany Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.2.3. United Kingdom Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.2.4. Italy Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.2.5. Spain Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.2.6. Rest of Europe Active Implantable Medical Devices Market Size in USD Million (2022-2032)
    • 7.3.3. Asia-Pacific
      • 7.3.3.1. China Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.3.2. Japan Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.3.3. India Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.3.4. Australia Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.3.5. South Korea Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.3.6. Rest of Asia-Pacific Active Implantable Medical Devices Market Size in USD Million (2022-2032)
    • 7.3.4. Rest of the World (RoW)
      • 7.3.4.1. Middle East Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.4.2. Africa Active Implantable Medical Devices Market Size in USD Million (2022-2032)
      • 7.3.4.3. South America Active Implantable Medical Devices Market Size in USD Million (2022-2032)

8. Active Implantable Medical Devices Market Company and Product Profiles

  • 8.1. Medtronic plc.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Johnson and Johnson Services, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Abbott
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Boston Scientific Corporation
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. LivaNova PLC.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Axonics, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Aleva Neurotherapeutics
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Sonova Holding AG
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Bioventus Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. CARMAT
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Jarvik Heart Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. BIOTRONIK SE & Co. KG
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. MicroTransponder Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. MED-EL Medical Electronics
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. NeuroPace, Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. NEVRO CORP.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Shree Pacetronix
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Cochlear Ltd.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Berlin Heart
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Blackrock Neurotech
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Active Implantable Medical Devices Market in Global (2022-2032)
  • Table 3: Active Implantable Medical Devices Market in Global by Product Type (2022-2032)
  • Table 4: Active Implantable Medical Devices Market in Global by End-User (2022-2032)
  • Table 5: Active Implantable Medical Devices Market in Global by Geography (2022-2032)
  • Table 6: Active Implantable Medical Devices Market in North America (2022-2032)
  • Table 7: Active Implantable Medical Devices Market in the United States (2022-2032)
  • Table 8: Active Implantable Medical Devices Market in Canada (2022-2032)
  • Table 9: Active Implantable Medical Devices Market in Mexico (2022-2032)
  • Table 10: Active Implantable Medical Devices Market in Europe (2022-2032)
  • Table 11: Active Implantable Medical Devices Market in France (2022-2032)
  • Table 12: Active Implantable Medical Devices Market in Germany (2022-2032)
  • Table 13: Active Implantable Medical Devices Market in the United Kingdom (2022-2032)
  • Table 14: Active Implantable Medical Devices Market in Italy (2022-2032)
  • Table 15: Active Implantable Medical Devices Market in Spain (2022-2032)
  • Table 16: Active Implantable Medical Devices Market in the Rest of Europe (2022-2032)
  • Table 17: Active Implantable Medical Devices Market in Asia-Pacific (2022-2032)
  • Table 18: Active Implantable Medical Devices Market in China (2022-2032)
  • Table 19: Active Implantable Medical Devices Market in Japan (2022-2032)
  • Table 20: Active Implantable Medical Devices Market in India (2022-2032)
  • Table 21: Active Implantable Medical Devices Market in Australia (2022-2032)
  • Table 22: Active Implantable Medical Devices Market in South Korea (2022-2032)
  • Table 23: Active Implantable Medical Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 24: Active Implantable Medical Devices Market in the Rest of the World (2022-2032)
  • Table 25: Active Implantable Medical Devices Market in the Middle East (2022-2032)
  • Table 26: Active Implantable Medical Devices Market in Africa (2022-2032)
  • Table 27: Active Implantable Medical Devices Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Active Implantable Medical Devices Market in Global (2022-2032)
  • Figure 3: Active Implantable Medical Devices Market in Global by Product Type (2022-2032)
  • Figure 4: Active Implantable Medical Devices Market in Global by End-User (2022-2032)
  • Figure 5: Active Implantable Medical Devices Market in Global by Geography (2022-2032)
  • Figure 6: Active Implantable Medical Devices Market in North America (2022-2032)
  • Figure 7: Active Implantable Medical Devices Market in the United States (2022-2032)
  • Figure 8: Active Implantable Medical Devices Market in Canada (2022-2032)
  • Figure 9: Active Implantable Medical Devices Market in Mexico (2022-2032)
  • Figure 10: Active Implantable Medical Devices Market in Europe (2022-2032)
  • Figure 11: Active Implantable Medical Devices Market in France (2022-2032)
  • Figure 12: Active Implantable Medical Devices Market in Germany (2022-2032)
  • Figure 13: Active Implantable Medical Devices Market in the United Kingdom (2022-2032)
  • Figure 14: Active Implantable Medical Devices Market in Italy (2022-2032)
  • Figure 15: Active Implantable Medical Devices Market in Spain (2022-2032)
  • Figure 16: Active Implantable Medical Devices Market in the Rest of Europe (2022-2032)
  • Figure 17: Active Implantable Medical Devices Market in Asia-Pacific (2022-2032)
  • Figure 18: Active Implantable Medical Devices Market in China (2022-2032)
  • Figure 19: Active Implantable Medical Devices Market in Japan (2022-2032)
  • Figure 20: Active Implantable Medical Devices Market in India (2022-2032)
  • Figure 21: Active Implantable Medical Devices Market in Australia (2022-2032)
  • Figure 22: Active Implantable Medical Devices Market in South Korea (2022-2032)
  • Figure 23: Active Implantable Medical Devices Market in Rest of Asia-Pacific (2022-2032)
  • Figure 24: Active Implantable Medical Devices Market in the Rest of the World (2022-2032)
  • Figure 25: Active Implantable Medical Devices Market in the Middle East (2022-2032)
  • Figure 26: Active Implantable Medical Devices Market in Africa (2022-2032)
  • Figure 27: Active Implantable Medical Devices Market in South America (2022-2032)
  • Figure 28: Market Drivers
  • Figure 29: Market Barriers
  • Figure 30: Market Opportunities
  • Figure 31: PORTER'S Five Force Analysis